ATE72123T1 - Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. - Google Patents

Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.

Info

Publication number: ATE72123T1
Authority: AT; Austria
Prior art keywords: virus; cell response; vaccine; generating; peptide
Prior art date: 1985-04-19

Application number

AT86301223T

Other languages

English (en)

Inventor

Ellen Heber-Katz

Bernhard Dietzschold

Original Assignee

Wistar Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-19

Filing date

1986-02-20

Publication date

1992-02-15

1986-02-20 Application filed by Wistar Inst filed Critical Wistar Inst

1992-02-15 Application granted granted Critical

1992-02-15 Publication of ATE72123T1 publication Critical patent/ATE72123T1/de

Links

230000005867 T cell response Effects 0.000 title abstract 3
230000002163 immunogen Effects 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title abstract 2
241000700605 Viruses Species 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 abstract 1
102000003886 Glycoproteins Human genes 0.000 abstract 1
108090000288 Glycoproteins Proteins 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
239000002502 liposome Substances 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
241001529453 unidentified herpesvirus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Dispersion Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT86301223T 1985-04-19 1986-02-20 Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. ATE72123T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72508785A	1985-04-19	1985-04-19
EP19860301223 EP0203676B1 (de)	1985-04-19	1986-02-20	Impfstoff für die Erzeugung einer gegen ein Virus schützenden immunogenen T-Zellen-Antwort

Publications (1)

Publication Number	Publication Date
ATE72123T1 true ATE72123T1 (de)	1992-02-15

Family

ID=24913110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT86301223T ATE72123T1 (de)	1985-04-19	1986-02-20	Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.

Country Status (4)

Country	Link
EP (1)	EP0203676B1 (de)
AT (1)	ATE72123T1 (de)
CA (1)	CA1265054A (de)
DE (1)	DE3683688D1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5837249A (en) *	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
US6024964A (en) *	1985-06-24	2000-02-15	Hoechst Aktiengesellschaft	Membrane anchor/active compound conjugate, its preparation and its uses
DE3937412A1 (de) *	1989-11-10	1991-05-16	Hoechst Ag	Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US6074650A (en) *	1985-06-24	2000-06-13	Hoechst Aktiengesellschaft	Membrane anchor/active compound conjugate, its preparation and its uses
LU86736A1 (fr) *	1987-01-15	1988-08-23	Univ Bruxelles	Liposomes sensibilises a des molecules antigeniques de parasites intracellulaires,procede pour les preparations et leurs applications comme moyens de diagnostic et comme agents d'immunisation
EP0290246A3 (de) *	1987-05-08	1990-01-31	The Wistar Institute Of Anatomy And Biology	Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
AU608354B2 (en) *	1987-07-30	1991-03-28	Wistar Institute, The	Vaccination against rabies-related viruses
CA1337115C (en) *	1987-07-30	1995-09-26	Bernhard Dietzschold	Vaccination against rabies-related diseases
WO1989002277A2 (en) *	1987-08-28	1989-03-23	Board Of Regents, The University Of Texas System	Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0432693A1 (de) *	1989-12-11	1991-06-19	Sumitomo Chemical Company, Limited	Für virusinfizierte Zellen cytotoxische Liposomen
US5543390A (en) *	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) *	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5827819A (en)	1990-11-01	1998-10-27	Oregon Health Sciences University	Covalent polar lipid conjugates with neurologically active compounds for targeting
US5256641A (en) *	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
FR2670787B1 (fr) *	1990-12-18	1995-06-23	Pasteur Institut	Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5871746A (en) *	1990-12-18	1999-02-16	Institut National De La Sainte Et De La Recherche Medicale (Inserm)	Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5554728A (en) *	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
US5955080A (en) *	1991-07-26	1999-09-21	Commonwealth Scientific And Industrial Research Organisation	Self-adjuvanting peptide vaccine delivery system and production thereof
CA2441809C (en)	2001-03-27	2014-07-22	Biomira, Inc.	Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
DE10148065A1 (de) *	2001-09-28	2003-04-17	Max Planck Gesellschaft	(Ester)-Lysolecithine in Liposomen
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
TW201204410A (en)	2004-04-01	2012-02-01	Oncothyreon Inc	Mucinous glycoprotein (MUC-1) vaccine
AU2006274651B2 (en)	2005-06-28	2012-09-27	Oncothyreon Inc.	Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
EP3527220A1 (de)	2010-08-12	2019-08-21	AC Immune S.A.	Manipulation von impfstoffen
CA2813833C (en) *	2010-10-26	2020-09-22	Ac Immune S.A.	Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2825972A1 (en)	2011-02-24	2012-08-30	Oncothyreon Inc.	Muc1 based glycolipopeptide vaccine with adjuvant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4762708A (en) *	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination

1986
- 1986-02-20 EP EP19860301223 patent/EP0203676B1/de not_active Expired - Lifetime
- 1986-02-20 AT AT86301223T patent/ATE72123T1/de not_active IP Right Cessation
- 1986-02-20 DE DE8686301223T patent/DE3683688D1/de not_active Expired - Lifetime
- 1986-04-16 CA CA000506804A patent/CA1265054A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE3683688D1 (de)	1992-03-12
EP0203676A2 (de)	1986-12-03
EP0203676B1 (de)	1992-01-29
EP0203676A3 (en)	1988-03-02
CA1265054A (en)	1990-01-30

Legal Events

Date	Code	Title	Description
1992-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE72123T1 (de)	1992-02-15	Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
ES2070866T3 (es)	1995-06-16	Vacunas recombinantes contra la coccidiosis.
ATE79548T1 (de)	1992-09-15	Herpes simplex virus subunitimpfstoff.
ES555668A0 (es)	1987-08-16	Un procedimiento para la preparacion de peptidos inmunogenicos sinteticos contra fmvd
AU4233585A (en)	1985-11-15	Vaccine against rabies and preparation process thereof
AU4826493A (en)	1994-04-12	Anti-feline immunodeficiency virus (fiv) vaccines
GB9814538D0 (en)	1998-09-02	Helicobacter pylori bacterioferritin
IT8021972A0 (it)	1980-05-09	Procedimento per la preparazione di n-fosfonometil glicina.
ES548052A0 (es)	1987-02-16	Procedimiento para preparar peptidos
BR9710849A (pt)	2000-01-11	Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
FI933210A0 (fi)	1993-07-14	Avirulent vaccin mot rabies
DK0463053T3 (da)	1998-10-07	Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
NO902352D0 (no)	1990-05-28	Fremgangsmaate for fremstilling av en vaksine mot dental karies, samt vaksineblandinger for anvendelse som nesedraaper
EP0179412A3 (de)	1988-08-24	Antigen-Peptidverbindungen
ATE95422T1 (de)	1993-10-15	Ein synthetisches nonapeptid zur verwendung als adjuvant.
AU8989491A (en)	1992-06-25	Protective plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens hrpii and serp, the preparation and use thereof
NZ224251A (en)	1991-09-25	Synthetic rhinovirus (hrv) peptides and vaccines
ES2058570T3 (es)	1994-11-01	Procedimiento para la obtencion de una vacuna antirrabica no virulenta.
ES515472A0 (es)	1984-04-16	Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
EP0290246A3 (de)	1990-01-31	Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
IT1233419B (it)	1992-03-31	Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
ATE159758T1 (de)	1997-11-15	Azelluläre impfstoffe
DK224288A (da)	1989-05-07	Fremgangsmaade til fremstilling af peptidiske synthoner